SEARCH RESULTS

31 RESULTS

Dennis Selkoe on Biogen/Eisai Halt Phase 3 Aducanumab Trials

COMMENT This morning’s news that an interim analysis by Biogen of their Phase 3 clinical trials of their anti-amyloid antibody called aducanumab showed a lack of clinical benefit is a huge disappointment for our patients and for the field of therapeutics for ...

Current Filters

  • TYPE: Comment x
  • Commentator: Selkoe, Dennis x

Remove all filters

Filter By

DATE RANGE
  • All
  • Past 7 Days
  • Past 30 Days
  • Past 90 Days
  • Past 12 Months
  • Specific Dates
    1. From
      To

TYPE